172 related articles for article (PubMed ID: 29108228)
1. CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice.
Sakakibara K; Sato T; Kufe DW; VonHoff DD; Kawabe T
Oncotarget; 2017 Oct; 8(45):78277-78288. PubMed ID: 29108228
[TBL] [Abstract][Full Text] [Related]
2. CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.
Mine N; Yamamoto S; Saito N; Yamazaki S; Suda C; Ishigaki M; Kufe DW; Von Hoff DD; Kawabe T
Mol Cancer Ther; 2011 Oct; 10(10):1929-38. PubMed ID: 21831962
[TBL] [Abstract][Full Text] [Related]
3. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Shapiro GI; Tibes R; Gordon MS; Wong BY; Eder JP; Borad MJ; Mendelson DS; Vogelzang NJ; Bastos BR; Weiss GJ; Fernandez C; Sutherland W; Sato H; Pierceall WE; Weaver D; Slough S; Wasserman E; Kufe DW; Von Hoff D; Kawabe T; Sharma S
Clin Cancer Res; 2011 May; 17(10):3431-42. PubMed ID: 21220472
[TBL] [Abstract][Full Text] [Related]
4. Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.
Mine N; Yamamoto S; Kufe DW; Von Hoff DD; Kawabe T
Mol Cancer Ther; 2014 Sep; 13(9):2215-25. PubMed ID: 25053821
[TBL] [Abstract][Full Text] [Related]
5. CBP501 suppresses macrophage induced cancer stem cell like features and metastases.
Mine N; Yamamoto S; Saito N; Sato T; Sakakibara K; Kufe DW; VonHoff DD; Kawabe T
Oncotarget; 2017 Sep; 8(38):64015-64031. PubMed ID: 28969049
[TBL] [Abstract][Full Text] [Related]
6. Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.
Maines LW; Keller SN; Smith CD
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069222
[TBL] [Abstract][Full Text] [Related]
7. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
[TBL] [Abstract][Full Text] [Related]
8. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T; Nguyen A; Misleh J; Cline VJ; Johns M; Shumway N; Paulson S; Siegel R; Larson T; Messersmith W; Richards D; Chaves J; Pierce E; Zalupski M; Sahai V; Orr D; Ruste SA; Haun A; Kawabe T
Eur J Cancer; 2024 Apr; 201():113950. PubMed ID: 38422585
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy.
Wang Y; Shen N; Wang Y; Li M; Zhang W; Fan L; Liu L; Tang Z; Chen X
Biomater Sci; 2021 Apr; 9(8):3019-3027. PubMed ID: 33656040
[TBL] [Abstract][Full Text] [Related]
11. Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.
Kozai H; Ogino H; Mitsuhashi A; Nguyen NT; Tsukazaki Y; Yabuki Y; Ozaki R; Yoneda H; Sato S; Hanibuchi M; Shinohara T; Nokihara H; Nishioka Y
Thorac Cancer; 2024 Feb; 15(5):369-378. PubMed ID: 38146645
[TBL] [Abstract][Full Text] [Related]
12. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.
Di Blasio S; Wortel IM; van Bladel DA; de Vries LE; Duiveman-de Boer T; Worah K; de Haas N; Buschow SI; de Vries IJ; Figdor CG; Hato SV
Oncoimmunology; 2016 Aug; 5(8):e1192739. PubMed ID: 27622063
[TBL] [Abstract][Full Text] [Related]
13. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
15. T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer.
Fu D; Wu J; Lai J; Liu Y; Zhou L; Chen L; Zhang Q
Am J Cancer Res; 2020; 10(2):473-490. PubMed ID: 32195021
[TBL] [Abstract][Full Text] [Related]
16. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
17. Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma.
Ursic K; Kos S; Kamensek U; Cemazar M; Scancar J; Bucek S; Kranjc S; Staresinic B; Sersa G
Bioelectrochemistry; 2018 Feb; 119():161-171. PubMed ID: 29024870
[TBL] [Abstract][Full Text] [Related]
18. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer.
Aranda F; Bloy N; Pesquet J; Petit B; Chaba K; Sauvat A; Kepp O; Khadra N; Enot D; Pfirschke C; Pittet M; Zitvogel L; Kroemer G; Senovilla L
Oncogene; 2015 Jun; 34(23):3053-62. PubMed ID: 25065595
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
20. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
